Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Boston Scientific Reveals FDA Nod, Launch Of INGENIO, ADVANTIO & INVIVE CRT-P

RELATED NEWS
Trade BSX now with 

Boston Scientific Corp. (BSX: Quote) unveiled FDA approval and market launch of its INGENIO and ADVANTIO pacemakers and INVIVE cardiac resynchronization therapy pacemakers, or CRT-P.

The INGENIO and ADVANTIO pacemakers feature RightRate pacing technology designed to treat chronotropic incompetence, or CI. CI is the inability of the heart to regulate its rate appropriately in response to physical activity, which may cause patients to feel tired or short of breath during daily activities such as walking or climbing stairs. The company noted that the first implant of the INGENIO pacemaker in the U.S. was performed on May 3 by Bruce Wilkoff, Director of Cardiac Pacing and Tachyarrhythmia Devices at the Cleveland Clinic.

In addition to RightRate, the INGENIO pacemaker offers Respiratory Rate Trend, or RRT, an exclusive feature that monitors respiration, a key vital sign. The INVIVE CRT-P offers RRT as part of HF Perspectiv, a comprehensive suite of heart failure diagnostics designed to provide health care professionals with additional information to guide treatment decisions.

The INGENIO, ADVANTIO and INVIVE devices are designed for use with Boston Scientific's new LATITUDE NXT Remote Patient Management system, which is currently under review by the FDA, and will enable physicians to conduct remote follow-ups of these device patients to monitor specific pacemaker information and heart health status.

Register
To receive FREE breaking news email alerts for Boston Scientific Corp and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The private sector in the eurozone logged a marginal upturn in October helped by an improvement in Germany, while France moved deeper into contraction, flash data from Markit Economics revealed Thursday. The headline flash Markit composite output index rose to 52.2 in October from a 10-month low of 52 in September. The score was forecast to fall to 51.5. After moving modestly higher in morning trading, stocks showed a substantial move to the downside over the course of the trading day on Wednesday. The major averages pulled back well off their highs for the session, sliding firmly into negative territory. Ebola "czar" Ron Kain is scheduled to meet with President Barack Obama on Wednesday as he begins his efforts to coordinate the government's response to the deadly disease. Klain, who previously served as chief of staff to Vice President Joe Biden and then-Vice President Al Gore, was named as Ebola Response Coordinator last Friday.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.